Compare VRA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | ACET |
|---|---|---|
| Founded | 1982 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 71.3M |
| IPO Year | 2010 | N/A |
| Metric | VRA | ACET |
|---|---|---|
| Price | $2.40 | $0.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.00 | ★ $8.50 |
| AVG Volume (30 Days) | 1.9M | ★ 2.6M |
| Earning Date | 12-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $324,296,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.45 |
| 52 Week High | $4.09 | $1.11 |
| Indicator | VRA | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 32.79 |
| Support Level | $1.39 | $0.46 |
| Resistance Level | $2.06 | $0.59 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 80.23 | 8.34 |
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.